STSA - Satsuma Migraine Failure And Other News: The Good Bad And Ugly Of Biopharma
Satsuma reports disappointing top-line data for Phase 3 trial
Satsuma Pharmaceuticals, Inc. (STSA) reported top-line results from its EMERGE efficacy trial assessing STS101 powder as an acute treatment for migraine. The top-line data showed favorable numerical differences for STS101 3.9 mg and 5.2 mg versus placebo on the pre-specified co-primary endpoints. However, the data did not show statistically significant difference for any of the dosage strength.
The Phase 3 EMERGE efficacy trial of STS101 is a multi-center, single-dose study. This randomized, double-blind, placebo-controlled, parallel group study involved more than 1,140 migraine patients in the United